$16.27▲ 1.72 (11.82%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.1× debt-to-equity).
low return on equity (-56%).
Quality
1.6
Health
9.7
Growth
4.7
Valuation
6.8
Sentiment
6
Analyst Target
$26.63
▲ +63.7% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-9.0×
next 12 months est.
Market Cap
$2.3B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-56.3%
return on equity
Beta
1.81
vs S&P 500
52-Week Range
$8 — $28
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Intellia Therapeutics, Inc. right now?
Intellia Therapeutics, Inc.'s Q·Score is 5.5/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: low return on equity (-56%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for NTLA?
The consensus price target for NTLA is $26.63, based on ratings from 19 Wall Street analysts. This is 63.7% above the current price of $16.27. Price targets are forward-looking estimates and not guarantees of future performance.
Is NTLA overvalued or undervalued?
Intellia Therapeutics, Inc. (NTLA) scores in line with sector averages on valuation metrics. The consensus analyst price target of $26.63 is 64% above the current price.
When does Intellia Therapeutics, Inc. report its next earnings?
Intellia Therapeutics, Inc.'s next earnings report is expected on approximately August 6, 2026.
What is Intellia Therapeutics, Inc.'s profit margin?
Intellia Therapeutics, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
Is Intellia Therapeutics, Inc.'s revenue growing?
Intellia Therapeutics, Inc. is reporting revenue declining 9.5% year-over-year.
How much debt does Intellia Therapeutics, Inc. have?
Intellia Therapeutics, Inc. has a debt-to-equity ratio of 0.13×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 6.10×, indicating comfortable short-term liquidity.